> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Emergent Resumption of Vaccine Production
- URL: https://www.fdaweb.com/fda-oks-emergent-resumption-of-vaccine-production/
- Published: 2021-07-29T12:00:00.000Z
- Updated: 2026-09-14T17:08:30.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5149814

FDA is allowing Emergent BioSolutions to resume production of the Johnson & Johnson Covid-19 vaccine at the company’s troubled Bayview manufacturing facility. The company [says](https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-resume-manufacturing-covid-19-vaccine?ref=fdaweb.com) that following an FDA order to halt vaccine production at Bayview, it worked closely with the agency and J&J to address quality concerns, including developing and executing an action plan and committing extensive resources to bring operations up to FDA standards.

“The American people should have high expectations of the partners the government chooses to help prepare them for disaster,” says Emergent CEO **Robert Kramer**, “and we have even higher expectations of ourselves. We have fallen short of those lofty ambitions over the past few months but resumption of manufacturing is a key milestone and we are grateful for the opportunity to help bring this global pandemic to an end. We’d like to thank our government partners as well as Johnson & Johnson for their support.”

The company says it expects to continue to work with FDA throughout the manufacturing process to help ensure the strength of the J&J Covid-19 vaccine supply chain.